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Abstract 
Background: Diabetes mellitus (DM) is considered a global epidemic, and patient self-management education and 
support are critical in preventing and reducing the risk of complications. Self-monitoring of blood glucose (SMBG) is 
essential for care of individuals with DM, helping patients to achieve and maintain target blood glucose levels. The 
purpose of this study is to compare the satisfaction of insulinized DM patients on SMBG with use of investigational 
blood glucose meter (BGM) versus their routine device.
Methods: A national, multicenter, open-label, phase 4 study was conducted on patients with type 1 or 2 DM under 
insulin therapy regimen, who were asked to use investigational BGM instead of their usual BGM device. The study 
was performed in 12 centers in Brazil for 12 weeks, with an extension period of 12 weeks. The primary endpoint was 
to measure the variation on the patients’ level of satisfaction with investigational versus routine BGM, between visits, 
using a Visual Analogue Scale (VAS). Secondary endpoints addressed handling aspects, satisfaction, adherence and 
level of functionality and safety of investigational BGM.
Results: The study included 292 patients (36.6 % DM1 and 63.4 % DM2), mean age 50.9 years old (±17.3 years), 
57.5 % females. There was statistically significant improvement in global satisfaction with investigational BGM com-
pared with routine BGM according to VAS [mean VAS score raised from 78.8 mm (SD = 18.0) to 90.8 mm (SD = 12.2) 
between visits]. After 12 weeks, level of satisfaction with investigational BGM according to questionnaires was superior 
to routine BGM regardless of age group (p < 0.001), type of DM (p < 0.001) or insulin regimen (p < 0.001). Investiga-
tional BGM was also regarded as safe, with 10 patients (3.4 %) reporting a total of 13 adverse events during the study.
Conclusions: Levels of satisfaction during SMBG were higher with use of investigational BGM and the device was 
deemed safe and easy to handle.
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Background
Diabetes mellitus (DM) is considered as a global epi-
demic, with a worldwide prevalence estimated in 9  % 
among adults aged >18 years in 2014 [1] and 1.5 million 
deaths reported in 2012 as a direct cause of the disease 
[2]. This is a complex, chronic illness and both types 
(DM1 and DM2) require continuous medical care with 
multifactorial risk-reduction strategies beyond glycemic 
control.
Patient self-management education and support are 
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complications. Among several actions that should be 
taken to manage DM is self-monitoring of blood glucose 
(SMBG). SMBG is an essential tool for the care of indi-
viduals with the disease, being important to help patients 
achieve and maintain target blood glucose levels in order 
to reduce the risk of diabetes-related complications [3].
SMBG is recognized as a fundamental component of 
effective diabetic self-management [4–6]. In patients with 
type 1 diabetes (DM1) it was associated with better results 
in controlling blood glucose levels [7]. In patients with 
type 2 diabetes (DM2) in use of insulin therapy, it opti-
mizes blood glucose control [8, 9]. Nevertheless, benefits 
of SMBG in patients with DM2 who are not using insulin 
are still controversial. Current evidence on this subject is 
mixed, with studies showing both significant and insignif-
icant glycemic benefits resulting from SMBG [8, 10, 11].
In any case, frequent SMBG is important to adequately 
manage type 1 or 2 DM. When used properly, glucose 
meters for self-measurement of blood glucose allow dia-
betes patients to determine their blood glucose level and 
can guide insulin dose adjustment [3, 11]. The Diabetes 
Control and Complications Trial among people with type 
1 DM clearly showed the efficacy of tight glycemic con-
trol in reducing diabetic complications [12, 13].
Modern glucose meters are small, easy to handle, and 
require very little blood volume (usually less than 5  μl), 
providing accuracy at rates of 95 %. Overall performance 
of SMBG systems is a combination of the analytical per-
formance of the instrument, proficiency of the patient, 
and quality of the test strips and the underlying measure-
ment technology, thereby allowing patients and clinicians 
to monitor glycemic control [3].
The objective of this study was to compare the patients’ 
satisfaction with the blood glucose meter (BGM) used in 
daily routine for self-monitoring blood glucose versus an 
investigational BGM device.
Methods
A national, multicenter, open-label, one arm, phase 4 
study was conducted on patients with type 1 or 2 DM 
under insulin therapy regimen. The study was performed 
in 12 centers in Brazil from April 2013 to December 2014, 
and compared patient’s satisfaction with the blood glu-
cose meter BGStar® (Sanofi-Aventis, Frankfurt, Germany) 
after 12 weeks of use in comparison to the previous BGM 
used in their daily routine, for SMBG. At the end of this 
period, patients could opt to continue using the investiga-
tional BGM for an additional period of 12 weeks (exten-
sion period). As the study design is a single arm, there was 
no need for randomization. 
The study comprised five visits and five questionnaires 
to be completed by patients, according to the study visit 
(Appendix). A questionnaire based on a Visual Analogue 
Scale (VAS) was used to assess patients’ global satisfac-
tion with BGM, and the others were seven-item ques-
tionnaires that evaluated patient general preferences on 
handling features of BGMs (Questionnaire 1, answered 
at visit 1); on handling features of previous BGM (Ques-
tionnaire 2, answered at visit 1); on handling features of 
investigational BGM after 12 and 24 weeks of use (Ques-
tionnaire 3, answered at visits 4 and 5); and adherence to 
the use of investigational BGM and its adequate operation 
along the study (Questionnaire 4, answered at visits 2–5).
The study selected patients with  ≥18  years old, both 
male and female, with type 1 or type 2 diabetes, receiving 
insulin for at least 2 years; with a stable insulin regimen 
and in use of any BGM for at least 6 months. The study 
also required that the patient had the ability to perform 
blood glucose self-monitoring. Patients on CSII were 
excluded from the study.
The primary endpoint was the comparison of the 
patients’ satisfaction with the investigational BGM after 
12 weeks of use versus their satisfaction with the previ-
ous BGM used in daily routine. Satisfaction was based 
on questionnaires completed by patients, such as Visual 
Analogue Scale (VAS) and preferences on handling fea-
tures of BGM (speed to obtain results, size, appearance, 
reliability and insulin dose adjustments). Secondary end-
points included comparison of patients’ global satisfac-
tion with the investigational BGM after 24 weeks of use 
compared to baseline and to week 12 levels of satisfac-
tion. Also, it included the evaluation of: patients’ general 
preferences on handling features of the investigational 
BGM and of previous BGM; patient general preferences 
on handling features of the investigational BGM after 12 
and 24 weeks of use; adherence to the use of the inves-
tigational BGM and its adequate operation along the 
study; frequency of hypoglycemic episodes during the 
study (including extension period) related to the study 
procedures; number of Product Technical Complaints 
(PTCs) during the study, including extension period; and 
safety information.
This study was performed in compliance with Good 
Clinical Practices, including the archiving of essential 
documents, and with the ICH Harmonized Tripartite 
Guideline on the Structure and Content of Clinical Study 
Reports, dated July 1996, using QSOP-004712 Version 
3.0. The study was approved by all local Institutional 
Review Boards (IRBs; by each participant site). As this 
study was not conducted in the USA, and following the 
sponsor’s policy, the study was not disclosed on Clinical-
Trials.gov.
Statistical methods
All patients who signed the informed consent form (ICF) 
were considered as screened. Patient who signed the ICF 
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and were not a screen failure were included in intent-to-
treat (ITT) population. All ITT patients who had used 
at least once the investigational BGM were also consid-
ered in the modified intent-to-treat (m-ITT) population. 
Safety population consisted of all enrolled patients. All 
efficacy analyses were based on m-ITT population, and 
all safety analyses on ITT population.
Quantitative data were summarized by descriptive sta-
tistics such as mean, standard deviation, minimum and 
maximum and the categorical data were summarized by 
absolute (n) and relative (%) frequency of occurrence.
All results were based on total number of patients with 
available information (i.e. patients who attended the visit 
and for whom the specific data was not missing). The 
type I error adopted for the statistical tests was 5 %. All 
analyses were conducted using SAS version 9.4.
Satisfaction analysis (overall satisfaction with the inves-
tigational BGM) were assessed using the Visual Analogue 
Scale (VAS) and a specific questionnaire of satisfaction 
with seven items, applied at initial visit (V1), final visit 
after 3  months (V4) and extension visit after 6  months 
(V5). For each efficacy endpoint (VAS and the sum of the 
seven-item satisfaction questionnaire), a model of analy-
sis of variance (ANOVA) was applied with a fixed factor 
of repeated measures (VISIT), since the same patient is 
evaluated in two or more visits. The main objective of 
the ANOVA model was to identify if there was a “VISIT 
effect”, i.e. to identify if there was any change in the 
patients satisfaction across V1, V4 and V5.
Global satisfaction was also analyzed in subgroups 
(age, type of diabetes and insulin delivery system). An 
ANOVA model was also applied in this case, including 
the subgroup factor and the interaction with VISIT. The 
objective was to identify if a possible change observed 
along the visits in the patients’ satisfaction was similar 
by each subgroup category. When the factor VISIT was 
significant in an ANOVA model including the extension 
period, multiple comparison tests were carried out.
Each of the individual seven-item questionnaire scores 
were also analyzed in order to see any specific change 
from V1 (satisfaction compared with previous BGM) and 
V4 (satisfaction after 12  weeks using the investigational 




Between 5th April 2013 and 16th June 2014, 293 patients 
were enrolled in the study. All of them had signed the 
informed consent form, but one was excluded (screen 
failure) due to the use of insulin pump therapy. ITT 
population was similar to the safety population and com-
prised 292 patients. From this total, 268 patients (91.8 %) 
constituted the modified-ITT (m-ITT) population, as 
8.2 % of the patients did not use at least once the investi-
gational BGM (Fig. 1).
From the ITT population, 270 (92.5  %) patients 
attended the endpoint visit (V4), 82.9  % accepted to 
participate in the extension period and 80.8  % indeed 
attended V5. Twenty-nine (9.9 %) patients did not com-
plete the study according to the protocol, wherein seven 
of them had agreed to proceed to extension visit, but did 
not perform V5 (Fig. 1). Reasons for the patients did not 
complete the study were: lost to follow up (n = 16), con-
sent withdrawal (n = 12) and death (n = 1).
Four patients were considered as protocol deviation. 
Two of them did not fulfill the criterion “type 2, receiving 
insulin for at least 2 years with a stable insulin regimen 
for at least 6 months”, one patient did not fulfill the crite-
rion “use of any BGM for at least 6 months, with ability 
to perform blood glucose self-monitoring” and the other 
one did not fulfill the criterion “age ≥18 years old”.
Age of patients ranged from 17.9 to 86.1  years, with 
mean age of 50.9 (SD = 17.3) and median of 54.7 years. 
Despite the protocol inclusion criteria “age  ≥18  years 
old”, one patient aging 17.9 years was screened and per-
formed all planned visits; this patient was considered 
for both ITT and m-ITT analyses. Regarding gender, 
124 (42.5 %) patients were male and 168 (57.5 %) female. 
Body mass index (BMI) ranged between 17.6 and 47.7 kg/
m2, with mean of 28.9 kg/m2 (SD = 5.3). Means of sys-
tolic and diastolic pressure were 129.9 (SD =  20.5) and 
78.4 (SD = 12.4) mmHg, respectively (Table 1).
Most patients (185; 63.4  %) had type 2 diabetes mel-
litus. Mean time of diabetes diagnosis was 15.0  years 
(SD = 9.1). Basal-bolus was the insulin regimen applica-
tion at baseline for most patients (60.6 %) (Table 1).
Patients’ satisfaction results
Adherence to investigational BGM was evaluated at visits 
(V2, V4 and V5) by an investigator. Adherence was catego-
rized, according to the protocol definition, as Total (BGM 
was used at least once a day), Partial (BGM was used at 
least once a day, between 2 and 6 days of the week) and 
No Adherence (BGM was used at most once a week). 
Most of patients (71.3 %) totally adhered to BGM at V2, 
but this number decreased at V4 (62.8 %) and extension 
visit V5 (52.8 %), while Partial adherence remained stable 
(Table 2).
The global satisfaction with the investigational BGM 
after 12  weeks of use was compared to the global sat-
isfaction with previous BGM, based on VAS score 
(0–100  mm) and on the sum of a seven-item question-
naire. In the satisfaction questionnaire based on VAS, 
higher values on the scale are associated to higher sat-
isfaction; moreover, in the analysis of the seven-items 
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questionnaire, a lower score is associated to higher satis-
faction. From the 268 patients of m-ITT population, 258 
patients attended V1 and V4, and answered the global sat-
isfaction questionnaire. Of these, 176 (68.2 %) assigned a 
higher VAS score after 12 weeks of use of investigational 
BGM compared with previous BGM, 47 (18.2  %) indi-
cated no change and 35 (13.6 %) assigned a lower score 
after 12  weeks. A statistically significant improvement 
of satisfaction was observed when using investigational 
BGM for 12 weeks: mean VAS score raised from 78.8 mm 
(SD =  18.0) at V1 to 90.8 mm (SD =  12.2) at V4. Mean 
difference on VAS score was 11.9 (SD = 20.4; p < 0.001; 
95 % CI 9.4–14.4 mm) (Table 3).
Mean change of VAS score from V1 to V4 was also 
analyzed for the subgroups: Type of diabetes, Insu-
lin regimen application and Age (Table  4). There was 
no observed statistically significant effect (p  =  0.221) 
for the interactions VISIT*TYPE, indicating that the 
increase in mean satisfaction with the use of investigation 
BGM for 12 weeks was similar for patients with T1DM 
(14.0 ± 20.8 mm) and T2DM (10.8 ± 20.2 mm). Regard-
ing the subgroup insulin regimen application, interac-
tion VISIT*REGIMEN was not statically significant 
(p = 0.133), showing that the increase in the satisfaction 
with the investigational BGM was similar for patients at 
basal-bolus (13.5  ±  20.0  mm) and at other application 
regimens (9.5 ± 20.9 mm).
Moreover, a statistically significant effect was observed 
for the interaction VISIT*AGE (p = 0.023). The increase 
observed in the satisfaction based on VAS after 12 weeks 
of use of investigational BGM was inversely propor-
tional to the age. By observing the same three age groups 
in the visit V1 (satisfaction with the previous BGM), we 
observed that younger patients (age <25 years) were more 
dissatisfied than older patients (age ≥65 years), according 
to Turkey’s method for multiple comparisons (17.6 ± 19.9 
versus 6.2  ±  19.6  mm, respectively; global significance 
level  =  0.05) for the age groups in V1. In the satisfac-
tion evaluation performed at V4 (after 12 weeks of use of 
investigational BGM), there was no statistically significant 
Fig. 1 Patient flow diagram. ITT intention-to-treat; m-ITT modified intention-to-treat; V4 visit 4; V5 visit 5; BGM blood glucose meter
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difference among the three age groups. It is also impor-
tant to note that in the group of patients with ≥65 years 
the initial evaluation was already high, thus the difference 
was not significant. Also, at week 12, all age groups 
showed very similar satisfaction levels according to VAS 
scores means, which may indicate that satisfaction with 
the investigational BGM may increase with its use, and 
the subsequent raise in the ability to handle it.
Regarding global satisfaction based on a seven-item 
questionnaire sum, 253 patients from the m-ITT popu-
lation (n  =  268) answered all questionnaires, and were 
therefore included in the analysis. The mean sum of 
questionnaire scores was 15.8 (SD = 3.8) at V1 and 12.0 
(SD = 3.4) at V4, meaning an improvement of satisfaction 
when using investigational BGM for 12 weeks (p < 0.001). 
There was no interaction effect of any of the subgroups 
tested—VISIT*TYPE (p  =  0.113), VISIT*REGIMEN 
(p =  0.439) and VISIT*AGE (p =  0.560)—meaning that 
changing of satisfaction score from V1 to V4 was similar 
for all age groups, both type 1 and type 2 diabetes, and 
also basal-bolus versus other insulin application regi-
mens. Global satisfaction with investigational BGM after 
12 weeks of use was also compared with previous BGM 
through each of the individual seven-item questionnaire. 
All seven-item scores (except item 6: “On average, how 
often do you stop to take the blood glucose tests recom-
mended by your doctor with the current BGM/inves-
tigational BGM?”) decreased significantly (p  <  0.001), 
indicating better satisfaction after 12  weeks usage of 
investigational BGM.
Global satisfaction levels after 24  weeks using investi-
gational BGM was compared to those obtain with previ-
ous BGM and investigational BGM after 12 weeks of use. 
Levels were based on VAS score (0–100 mm) and on the 
sum of a seven-item questionnaire. From the 268 patients 
of m-ITT population, 224 patients attended V1, V4 and V5 
and answered the global satisfaction questionnaire based 
Table 1 Demographic and  clinical characteristics of 
patients (ITT)
a Only patients who couldn’t precise the year of the disease onset
b At baseline visit
ITT intent-to-treat; BMI body mass index
Characteristics Total of available  
patients (n)
Age (years)
Mean ± SD 50.9 ± 17.3
Minimum–maximum 17.9–86.1
N of patients (%)
<25 years 27 (9.2 %)
≥25 to <65 years 197 (67.5 %)
≥65 years 68 (23.3 %) 292
Sex—n (%)
Male 124 (42.5 %)
Female 168 (57.5 %) 292
BMI (kg/m2)
Mean ± SD 28.9 ± 5.3
Minimum–maximum 17.6–47.7 289
Systolic BP (mmHg)
Mean ± SD 129.9 ± 20.5
Minimum–maximum 90–240 291
Diastolic BP
Mean ± SD 78.4 ± 12.4
Minimum–maximum 51–170 291
Type of diabetes mellitus—n (%)
Type 1 107 (36.6 %)
Type 2 185 (63.4 %) 292
Insulin regimen applicationb—n (%)
Basal-bolus 177 (60.6 %)
Others 115 (39.4 %) 292
Table 2 Adherence to BGM according to the study center, 
by visit (ITT)
Total BGM was used at least once a day; Partial BGM was used at least once a 
day, between 2 and 6 days of the week; No BGM was used at most once a week
Visit Study period Extension period
V2 V4 V5
Week Week 4 Week 12 Week 24
Adherence
Total 194 (71.3 %) 167 (62.8 %) 122 (52.8 %)
Partial 61 (22.4 %) 67 (25.2 %) 56 (24.2 %)
No 17 (6.3 %) 32 (12.0 %) 53 (22.9 %)
Total of available 
patients
272 (100 %) 266 (100 %) 231 (100 %)
Table 3 Overall satisfaction with previous BGM and inves-
tigational BGM through Visual Analogue Scale (VAS), dur-
ing the study period (m-ITT)
ITT intention-to-treat; SD standard deviation; CI confidence interval
Visit Study period Difference
V1 V4
Day/week Day 1 Week 12 VASV4–VASV1
VAS (0–100 mm)
Mean ± SD 78.8 ± 18 90.8 ± 12.2 11.9 ± 20.4
Median 80.0 94.0 10.0
Q1–Q3 70 to 90 86 to 100 0 to 20
Minimum–maximum 0 to 100 14 to 100 −61 to 90
CI 95 % 76.6 to 81.0 89.3 to 92.2 9.4 to 14.4
Total of available patients 258 (100 %) 258 (100 %) 258 (100 %)
p value (visit) p < 0.001
Page 6 of 9Hissa  Diabetol Metab Syndr  (2016) 8:66 
on VAS; and 219 answered the seven-item questionnaire. 
Mean VAS score raised from 78.6 mm (SD = 18.4) at V1 to 
91.3 mm (SD = 11.3) at V4 and remained almost the same 
at V5, with mean score of 90.3 mm (SD = 13.5) (Table 5). 
Mean sum of satisfaction questionnaire score was 15.7 
(SD = 3.9) at V1, 11.8 (SD = 3.3) at V4 and 12.0 (SD = 3.6) 
at V5. Multiple comparisons showed higher mean score at 
V1 than V5, indicating an increase in the satisfaction after 
using the investigational BGM for 24  weeks, but similar 
mean scores at V4 and V5, showing that the satisfaction 
was maintained from V4 to V5 (Table 6).
Safety Results
Ten (3.4  %) patients reported a total of 13 adverse 
events during the study period, including the 12-week 
extension. One patient reported four events, and all the 
others presented only one event each. One (0.3 %) patient 
had an adverse event considered serious: fall with mild 
traumatic head injury due to symptoms of hypoglycemia; 
this event was the only one related to the investigational 
BGM (product technical complaint, PTC). This case was 
analyzed by the legal manufacturer; the malfunction of 
the device was detected and subsequently corrected. 
Two (0.7  %) patients reported adverse events related to 
hypoglycemia: 1 (0.3  %) patient at V5 (considered seri-
ous, with blood glucose level ≤36 mg/dl), and 1 (0.3 %) 
patient at V2 (considered non-serious, with blood glucose 
level ≤70 mg/dl). None of the events resulted in perma-
nent discontinuation of BGM use (Table 7).
There were 21 (7.2 %) patients with at least one PTC, 
resulting in 27 reported PTCs. Nineteen PTCs were 
reported by the patients, 4 by the investigators and four 
by the study staff.
Discussion
Self-management of diabetes remains the cornerstone of 
diabetes care. An overall self-management strategy would 
be greatly beneficial to people with diabetes as well as 
to their families. Major clinical trials of insulin-treated 
patients have included SMBG as part of the multifacto-
rial interventions to demonstrate the benefit of inten-
sive glycemic control on diabetes complications. SMBG 
is thus an integral component of effective therapy. Also, 
evidence points out that more frequent self-monitoring 
of blood glucose levels is associated with clinically and 
statistically better glycemic control regardless of diabetes 
type or therapy [14].
Table 4 Overall satisfaction with previous BGM and with investigational BGM after 12 weeks of use, based on Visual Ana-
logue Scale (VAS) by age, diabetes type and insulin regimen (m-ITT)
a In the group with ≥65 years the initial evaluation was already high, thus the difference wasn’t significant







Day/week Day 1 Week 12 VASV4–VASV1
Mean ± SD Mean ± SD Mean ± SD VISIT: p < 0.001
Diabetes type
Type 1 73.1 ± 17.2 87.2 ± 13.4 93 14 ± 20.8 VISITaTYPE: p = 0.221
Type 2 82 ± 17.7 92.8 ± 11 165 10.8 ± 20.2
Insulin application regimen
Basal-bolus 76 ± 18 89.4 ± 12 158 13.5 ± 20 VISIT: p < 0.001
Other 83.3 ± 17.2 92.8 ± 12.2 100 9.5 ± 20.9 VISITaREGIMEN: p = 0.133
Age group
<25 years 72 ± 19.7 89.6 ± 11.4 24 17.6 ± 19.9 VISIT: p < 0.001
25 to <65 years 77.9 ± 18.6 91.2 ± 11.4 171 13.3 ± 20.5 VISITaAGE: p = 0.023
≥65 years 83.8 ± 14.2a 90 ± 14.4 63 6.2 ± 19.6
Table 5 Overall satisfaction with previous BGM and inves-
tigational BGM based on Visual Analogue Scale (VAS), dur-
ing the study period and extension (m-ITT)
Study period Extension period
Visit V1 V4 V5
Day/week Day 1 Week 12 Week 24
VAS (0–100 mm)
Mean ± SD 78.6 ± 18.4 91.3 ± 11.3 90.3 ± 13.5
Median 80.0 94.5 95.0
Q1–Q3 70–90.5 90–100 86–100
Minimum–maximum 0–100 14–100 10–100
Total of available patients 224 (100 %) 224 (100 %) 224 (100 %)
p value (visit) p < 0.001
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SMBG should be considered and evaluated in conjunc-
tion with all other aspects of diabetes self-management 
and care. The Canadian Diabetes Association (CDA) 
clinical practice guidelines for prevention and manage-
ment of diabetes recommend that SMBG should be indi-
vidualized for each person with diabetes based on their 
circumstances and needs, and the American Diabetes 
Association (ADA) guidelines recommend that patient’s 
specific needs and goals should dictate SMBG frequency 
and timing [4, 15]. This would help individuals to avoid 
hypoglycemic episodes during dose modifications, to 
correctly adjust medications, to evaluate individual 
response to therapy and assess if glycemic targets are 
being achieved [4, 8, 15].
Determination of blood glucose values through BGM 
should be performed regularly by insulin-treated diabetic 
patients, and the values obtained from these glucose 
readings should be used to direct and guide insulin dos-
ing on daily basis. In order to allow good treatment effi-
cacy and safety, BGMs need to be robust, easy to use, 
accurate and reliable [3].
Programmatic, structured SMBG contributes to sig-
nificant improvement in glycemic control in diabetic 
patients under insulin regimen [10]. But SMBG accuracy 
depends on the instrument and user, so these are impor-
tant aspects to be considered. Optimal use of SMBG 
requires proper review and interpretation of data, both 
by patients and physicians: patients should be taught 
how to use SMBG data to adjust food intake, exercise, or 
pharmacological therapy to achieve specific goals as well 
as to monitor and prevent asymptomatic hypoglycemia 
and hyperglycemia [4].
In an accuracy study, conducted in accordance with 
the ISO 15197 standards, BGStar demonstrated reliable 
results compared with other glucometers available on 
the European market. Results of this study suggest that 
patients preferred choosing BGStar than other glucom-
eters due to the facility regarding the use, storage and 
analysis memory available in the software [3].
In the Precision trial, BGStar demonstrated similar 
accuracy compared with other monitoring technologies 
used, with high intra-method and inter-method results, 
suggesting that BGStar is a precise and accurate method 
of glucose monitoring with many resources, includ-
ing electrochemistry dynamics, which improve diabetes 
management experience for patients [16].
SMBG can be considered the primary technique to 
assess the effectiveness of the patient glycemic control 
plan and the satisfaction with a BGM should be a key 
point in the management of diabetes, particularly among 
insulin-treated patients. A new BGM device could poten-
tially contribute to stimulate the patients to better control 
glycemia. This multicentric study conducted in Brazilian 
patients diagnosed with type 1 and type 2 diabetes dem-
onstrated that the investigational BGM received positive 
reviews by patients regarding its speed to obtain results, 
size and appearance, reliability, insulin dose adjustments 
and an overall satisfaction score.
The limitations of this study, is that when a new inter-
vention is introduced there will be an expected level of 
satisfaction because this is something new and different 
to what the consumer is used to. Others studies are nec-
essary to confirm our data.
Conclusions
The values obtained from glucose readings are used to 
direct and guide insulin dosing on a daily basis. Thus, fre-
quent self-monitoring of blood glucose levels is associated 
with better glycemic control. In this regard, appropriate 
Table 6 Sum of  scores of  satisfaction questionnaire with   
previous BGM and  investigational BGM, during  the study 
period and extension (m-ITT)
Study period Extension period
Visit V1 V4 V5
Day/week Day 1 Week 12 Week 24
Sum of scores
Mean ± SD 15.7 ± 3.9 11.8 ± 3.3 12 ± 3.6
Median 16.0 11.0 11.0
Q1–Q3 13–18 9–14 9–14
Minimum–maximum 7–29 7–24 7–26
Total of available patients 219 (100 %) 219 (100 %) 219 (100 %)
p-value (visit) p < 0.001
Table 7 Adverse events (ITT)
AE adverse event; SAE serious adverse eventa
N. of patients  
(%)
N. of events
N. (%) of patients with any AE 10 (3.4 %) 13
SAE 1 (0.3 %) 1
Criterion for SAE
Life-threatening 1 (0.3 %) 1
Intensity
Mild 8 (2.7 %) 11
Moderate 1 (0.3 %) 1
Severe 1 (0.3 %) 1
Treatment/corrective therapy
No 8 (2.7 %) 11
Yes 2 (0.7 %) 2
Related with investigation BGM technical complaint
Yes (serious) 1 (0.3 %) 1
N. of patients without any AE 282 (96.6 %)
Total of available patients 292 (100 %)
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use of structured SMBG significantly improves glycemic 
control and facilitates more timely/aggressive treatment 
for patients with diabetes mellitus [10, 14].
The study showed that levels of satisfaction during 
SMBG were higher with the use of investigational BGM 
than with routine BGM and the device was deemed safe 
and easy to handle.
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